NBRV - ナブリバ・セラピュ―ティクス (Nabriva Therapeutics plc)

NBRVのニュース

   Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%  2020/06/10 12:39:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
   Implied Volatility Surging for Nabriva (NBRV) Stock Options  2020/06/01 12:40:00 Zacks Investment Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
   Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)  2020/05/07 12:32:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick  2020/04/14 12:59:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
   Will Nabriva Therapeutics Continue to Surge Higher?  2020/01/22 13:24:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
   Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%  2020/06/10 12:39:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
   Implied Volatility Surging for Nabriva (NBRV) Stock Options  2020/06/01 12:40:00 Zacks Investment Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
   Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)  2020/05/07 12:32:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick  2020/04/14 12:59:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
   Will Nabriva Therapeutics Continue to Surge Higher?  2020/01/22 13:24:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
   Will Nabriva Therapeutics Continue to Surge Higher?  2020/01/22 13:24:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
   The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering  2020/01/07 12:57:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
   Nabriva's stock soars after resubmitting NDA for UTI treatment  2019/12/20 11:44:00 MarketWatch
Shares of Nabriva Therapeutics PLC soared 10.5% in premarket trading Friday, after the biotechnology company said it resubmitted its new drug application…
   Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio  2019/11/21 00:49:10 Benzinga
Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) shares have gained about 46% year-to-date. With the average analyst target being $8.42, the shares are primed for further upside provided upcoming catalysts pan out in favor of the company. Benzinga is profiling Nabriva for the benefit of investors ahead of some key catalytic events. Dublin, Ireland-based Nabriva, founded in 2006, is a commercial-stage biotech developing antibiotics to treat infectious diseases. The Pipeline Lefamulin Nabriva has a commercial product in lefamulin IV/oral, which was approved by the FDA in August for treating community-acquired bacterial pneumonia, or CABP. It was commercially launched in September in IV along with oral formulations under the brand name Xenleta. Lefamulin is a semi-synthetic compound that inhibits the synthesis of bacterial protein, which is essential for the pathogen to grow. The mode of action is through binding to the peptidyl transferase center present in the ribosome of the bacteria, interfering with the interaction of protein production at two key sites — the A site and P site — that inhibit protein production and in turn the growth of bacteria.
   Nabriva Therapeutics (NASDAQ:NBRV) Stock Rating Lowered by ValuEngine  2019/11/18 09:18:30 Modern Readers
ValuEngine cut shares of Nabriva Therapeutics (NASDAQ:NBRV) from a hold rating to a sell rating in a report published on Thursday morning, ValuEngine reports. Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Nabriva Therapeutics from a buy rating to a hold rating in a report on Friday, […]

calendar